Kleiner-Perkins and Genentech: When Venture Capital Met Science Harvard Case Solution & Analysis

Genentech is a rare success in the biotechnology industry. Hundreds of billions of dollars of venture capital was invested without the expected effect of transformation. Founded in 1976, Genentech was to develop a new science of recombinant DNA into viable therapeutic products with mass market appeal, the fact that most scientists agree, at least a decade. Founders, Herbert Boyer and Robert Swanson had limited financial resources, so they turned to Tom Perkins, co-founder of Kleiner Perkins-, for venture capital financing. Genentech developed by an effective union between scientific thinking and venture capital. In 1980, Genentech's IPO valued at $ 300 million. In 2009, it was fully acquired by the Swiss medical company Roche, for $ 47 billion. Roche held a majority stake in the company since 1990. "Hide
by G. Felda Hardymon, Tom Nicholas Source: Harvard Business School 17 pages. Publication Date: October 27, 2012. Prod. #: 813102-PDF-ENG

Kleiner-Perkins and Genentech: When Venture Capital Met Science Case Solution Other Similar Case Solutions like

Kleiner-Perkins and Genentech: When Venture Capital Met Science

Share This